Vyome Holdings, Inc. (NASDAQ:HIND) Receives $15.00 Average Target Price from Analysts

Vyome Holdings, Inc. (NASDAQ:HIND) has received an average rating of “Hold” from the five research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $15.00.

Several equities research analysts have weighed in on HIND shares. Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Finally, Litchfield Hills Research initiated coverage on shares of Vyome in a report on Monday, May 4th. They set a “buy” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC purchased a new position in Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned about 0.80% of Vyome at the end of the most recent quarter. 22.06% of the stock is owned by institutional investors.

Vyome Price Performance

Vyome stock opened at $1.99 on Wednesday. The stock has a market capitalization of $13.97 million, a price-to-earnings ratio of -0.16 and a beta of 1.49. Vyome has a 1-year low of $1.75 and a 1-year high of $18.60. The business has a fifty day moving average price of $2.20 and a 200-day moving average price of $2.38.

Vyome (NASDAQ:HIND) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter. On average, equities research analysts anticipate that Vyome will post -0.6 earnings per share for the current fiscal year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.